We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stakeholders Say FDA Guidance on Post-Approval Changes for Biologics Needs Clarification
Stakeholders Say FDA Guidance on Post-Approval Changes for Biologics Needs Clarification
The FDA’s draft guidance on post-approval manufacturing changes for biological products needs work to clarify how it fits with previous agency documents, according to written comments on the draft, which were due last week.